share_log

JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $22

Benzinga ·  May 8 14:08

JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and lowers the price target from $24 to $22.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment